OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
OSI Pharmaceuticals
Study ID
NCT00036647
Phase
PHASE3
Status
Completed

Conditions

  • Carcinoma, Non-small-cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).

Key Dates

Start date
Nov 1, 2001
Status verified
Jun 2015
Primary completion
Jan 30, 2004
Completion
Jan 30, 2004

Study Design

Enrollment
731 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
University of Chicago Medical CenterChicagoIllinois60637-
University of WashingtonSeattleWashington98109-

Find similar trials in Chicago, IL

By research site
University of Chicago Medical Center· Chicago, ILUniversity of Washington· Seattle, WA

Related Studies